Home › Drug Codes › NOC Codes › LYTENAVA
HCPCS Unassigned

LYTENAVA

bevacizumab-vikg · Outlook Therapeutics

Login to unlock all benchmarks
Miscellaneous Code ?
J3590
bill now · NOC code
Permanent Code ?
None yet
not published by CMS
WAC ?
Subscribe to view
AWP ?
Subscribe to view
NDCs Listed
1
Subscribe to view

Drug & Product Overview

Proposed Billing Descriptor Available at HCPCS code assignment
Miscellaneous Billing Code J3590
FDA Approval Date July 24, 2026
Manufacturer Outlook Therapeutics
Active Ingredient bevacizumab-vikg
Route of Administration Intravitreal
Dosage Form Injection

How to Bill LYTENAVA Now

Until CMS assigns LYTENAVA its own code, bill it with J3590, the code for unclassified biologics, and identify the product by its NDC. Once a permanent code takes effect, J3590 claims for LYTENAVA will be denied.

Setting Claim Form Billing Code Notes
Physician office / Part B CMS-1500 / 837P J3590 Enter the drug name, dose and NDC in Item 19 (or the 837P equivalent). The MAC prices the claim manually.
Hospital outpatient (OPPS) UB-04 / 837I C9399 Unclassified drug or biological. Separately payable and priced manually by the MAC.
Required Claim Documentation
Drug name and dosage administered National Drug Code (NDC) of the product given Total quantity administered, in the applicable unit of measure Date the drug was administered

About LYTENAVA

LYTENAVA (bevacizumab-vikg) is an intravitreal injection from Outlook Therapeutics for patients with neovascular (wet) age-related macular degeneration (nAMD). It was approved by the FDA on July 24, 2026.

LYTENAVA Pricing & NDCs

Package WAC and AWP for each NDC, updated monthly. There's no ASP payment limit until a permanent code takes effect.

NDC Code Package WAC AWP

1 NDC on file. Subscribe to see its package, WAC and AWP, with monthly history.

HCPCS Code Status

As of Nov 15, 2026
Billed under today
J3590
Unclassified biologics
Permanent code
Not published yet

CMS publishes new drug codes each quarter. This page shows the code and its effective date once it does.

A miscellaneous code is valid only until a drug’s own code takes effect. Confirm coding with your payer before billing.

LYTENAVA Clinical Information

Treated Diseases & Conditions
Patients with neovascular (wet) age-related macular degeneration (nAMD)

Try Pro free for 7 daysUpgrade to ProAdd Analytics and full history with Pro

Pro includes:

  • ASP, WAC and AWP for every drug
  • NDC package pricing
  • 10+ years of price history
  • Side-by-side Analytics in the Comparative Report

Card required · cancel anytime

Frequently Asked Questions

What HCPCS code is used for LYTENAVA?

J3590 (unclassified biologics) in the physician office, and C9399 in the hospital outpatient setting, until CMS assigns a permanent code.

What NDC goes on a LYTENAVA claim?

The NDC of the package you administered. Subscribers can see LYTENAVA’s NDCs with package, WAC and AWP.

When will LYTENAVA get a permanent J-code?

CMS has not published one yet. CMS publishes permanent codes in its quarterly coding decisions; this page will show the code and effective date once they are out.

Where can I find the full prescribing information?

Free account · J3590

LYTENAVA pricing you won’t find in public files

Create a free account to search every drug code, then try Pro free for 7 days to see WAC and AWP for each NDC.

  • Free: payment limits for every code
  • 7-day Pro trial: WAC and AWP for each NDC

Unlock with a 7-day Pro trial

WAC per package
Locked
AWP per package
Locked

10+

years of ASP, WAC and AWP price history

14,000+

NDC-to-HCPCS alignments built in-house, nearly twice the public crosswalks

Create your free account

  1. 1 Personal Info
  2. 2 About You
  3. 3 Credentials

Please use your company email. Personal addresses like Gmail or Yahoo aren’t accepted.

Personal Info

Already have an account? Log In